An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...

WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® ...

Acalabrutinib with bendamustine and rituximab is now an FDA-approved treatment for patients with previously untreated mantle ...

The Bruton tyrosine kinase inhibitor was approved in combination with bendamustine and rituximab in previously untreated ...

Discover how exercise enhances cancer treatment effectiveness, boosts immunity, and improves patient outcomes with ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.

Sergio A. Giralt, MD, discusses how rituximab plays a key role in treating chronic graft-vs-host disease. It is often used in combination with ibrutinib to enhance therapeutic outcomes. He reviews the ...

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...

Calquence in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients ...

To stabilize this condition we started rituximab therapy immediately after the third cycle of immunoadsorption, with 375 mg/m 2 rituximab being administered intravenously once weekly for 4 weeks.

An international team of researchers led by the University of California San Diego has developed a new strategy to enhance ...

Healio spoke with Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, about results from the inMind ...